After successful clinical trials last spring, two new colon cancer drugs are expected to receive FDA approval next year. Imclone Systems' and Bristol-Myers Squibb's Erbitux will be used in patients who already have failed other drug regimens, and Genentech's Avastin will be prescribed for first-line use in patients initially diagnosed with advanced color cancer.

Full Story:

Related Summaries